Ground-breaking results in Phase 2 scleroderma study by Certa Therapeutics demonstrates improvement in more than 60% of patients ...Middle East

PR Newswire - News
Data from Certa Therapeutics' Phase 2 clinical trial with development candidate FT011 demonstrates clinically meaningful improvements for more than 60 percent of patients with scleroderma after 12 weeks of treatment; Clinically meaningful improvements were reported in CRISS (the key...

Hence then, the article about ground breaking results in phase 2 scleroderma study by certa therapeutics demonstrates improvement in more than 60 of patients was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Ground-breaking results in Phase 2 scleroderma study by Certa Therapeutics demonstrates improvement in more than 60% of patients )

Apple Storegoogle play

Last updated :

Also on site :



Latest News